Single Telomere Length Analysis: An Independent Prognostic Marker for Cancer Patients

TeloNostiX Ltd通过单端粒长度分析（STELA）对慢性淋巴细胞性白血病（CLL）进行的预测测试有助于解决两个重大的全球医疗保健挑战：1)患者分层和2)精准医学（PMC支持该项目的信函可根据要求提供）。我们寻求资金以实现对我们技术发展至关重要的两个具体目标：(i)通过在操作环境中进行后勤评估，证明端粒检测在CLL患者常规临床管理中的技术可行性；㈡通过建立卫生经济学模型，为国民保健服务采用STELA提供财务理由。关键的焦点将是评估使用STELA将CLL患者分为风险组的潜力，基于他们是否会经历临床进展和需要治疗。该分析将包括文献综述、证据综合和护理途径分析。我们还将与一家全球端粒测试分销商合作，并利用当前的市场报告分析癌症预后市场，以进一步量化商机。

A case study for Innovate UK's Precision Medicine Catapult (PMC) (whose activities now fall under the Medicines Discvovery Catapult (MDC)), TeloNostiX Ltd's prognostic test for Chronic Lymphocytic Leukaemia (CLL) through Single Telomere Length Analysis (STELA) helps address two significant global healthcare challenges: 1) patient stratification and 2) precision medicine (a letter in support of the project from the PMC is available upon request). We seek funding to achieve two specific objectives critical to the development of our technology: (i) Demonstrate the technical feasibility of telomere testing in the routine clinical management of CLL patients by performing a logistical evaluation within an operational environment; (ii) Create a financial justification for NHS adoption of STELA by undertaking health economics modelling. The key focus will be to evaluate the potential for using STELA to stratify CLL patients into risk groups based on whether they will undergo clinical progression and require treatment. This analysis will consist of a literature review, evidence synthesis, and care pathway analysis. We will also engage with a global distributor of telomere tests and analyse the cancer prognostics market using current market reports to further quantify the business opportunity.